<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2016100825031N5</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2016-11-08</date_registration>
      <primary_sponsor>Arak University of Medical Sciences</primary_sponsor>
      <public_title>Effect of Ginger (Zingiber Officinale) and Chamomile Mixed Sachet with Honey in The Treatment of Primary Dysmenorrhea</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the Efficacy of Ginger-Chamomile Mixed Sachet and Honey with Mefenamic Acid in The Treatment of Primary Dysmenorrhea and Associated Symptoms of Female Students that Living in the Arak University of Medical Sciences Dormitory: Randomized Controlled Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2016-10-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>280</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/21012</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: For Blindness and randomization will be used from numbered closed envelopes and block sampling, Blinding description: For Blindness will be used from numbered closed envelopes. Patients, researcher, physicians and statistical adviser do not know about the type of drug and groupings.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Primary dysmenorrhoea.</hc_freetext>
      <i_freetext>Intervention 1: Group 1: sachet containing 1000 mg of ginger root powder and 5000 mg of chamomile with a teaspoonful of honey; 3 time a day, from 2 day before the beginning of menstrual cycle until 5 day. Intervention 2: Group 2: sachet that contain 1000 mg of ginger root powder with a teaspoonful of honey; 3 time a day, from 2 day before the beginning of menstrual cycle until 5 day. Intervention 3: Group 3: sachet that contain 5000 mg of chamomile with a teaspoonful of honey; 3 time a day, from 2 day before the beginning of menstrual cycle until 5 day. Intervention 4: Group 4: 250 mg mefenamic acid capsule manufactured by Raha pharmaceutical company; 3 time a day, from 2 day before the beginning of menstrual cycle until 5 day.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fatemeh Shabani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Nursing Faculty, Arak University of Medical Sciences, Arak, Iran</address>
        <city>Arak</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3819693345</zip>
        <telephone>+98 86 3417 3524</telephone>
        <email>f.shabani@arakmu.ac.ir</email>
        <affiliation>Arak University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Fatemeh Nejatbakhsh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Traditional Medicine Faculty, Tehran University of Medical Sciences, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1417733161</zip>
        <telephone>+98 21 8899 0837</telephone>
        <email>nejatbakhsh@tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Between 18 to 30 years old
Unmarried
The menstruation pain is started before 20 years old
Regular menstrual cycles between 21 to 35 days
Menstrual bleeding without passing clots
Menstrual pain start a few hours before menstrual bleeding and to continue for 5 days
Lack of chronic diseases
Without peptic ulcer or duodenal ulcer
Do not consume anticoagulant drugs
Lack of burning, itching and abnormal vaginal discharge
Without history of allergy to medicinal plants
Lack of stress in the past two months
Do not have to take medicine or special diet and smoking
Without history of pelvic inflammatory disease
Without history of gynecologic surgery
Do not transfer or relocation during the next 6 months
Do not have pain in all the time of menstrual bleeding
Do not consume oral contraceptives
Do not consume drugs class of benzodiazepines, barbiturates, narcotics and some antidepressants, such as fluoxetine
Avoiding to use alcohol, aspirin, warfarin and heparin
Without having specific diseases of liver, kidney and diagnosed depression</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>30 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Patient's refusal to participate in the study
Consume drugs irregularly
The incidence of significant stress factors during the study
The incidence of any disease that requires to consume drugs, nutritional supplements or vitamins for long-term
Doing any type of surgery during the study
Marriage or change location
Do not fill out the questionnaire
Unwillingness to continue consume their medication by patients
Avoiding the consume of medication as a single dose</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N94.4</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Primary dysmenorrhoea</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Group 1: sachet containing 1000 mg of ginger root powder and 5000 mg of chamomile with a teaspoonful of honey; 3 time a day, from 2 day before the beginning of menstrual cycle until 5 day</i_keyword>
      <i_keyword>Group 2: sachet that contain 1000 mg of ginger root powder with a teaspoonful of honey; 3 time a day, from 2 day before the beginning of menstrual cycle until 5 day</i_keyword>
      <i_keyword>Group 3: sachet that contain 5000 mg of chamomile with a teaspoonful of honey; 3 time a day, from 2 day before the beginning of menstrual cycle until 5 day</i_keyword>
      <i_keyword>Group 4: 250 mg mefenamic acid capsule manufactured by Raha pharmaceutical company; 3 time a day, from 2 day before the beginning of menstrual cycle until 5 day</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The severity of bleeding. Timepoint: Before intervention and after the first and third menstrual cycle. Method of measurement: (PBACs) Pictorial Blood Loss Assessment Chart.</prim_outcome>
      <prim_outcome>Duration of bleeding. Timepoint: Before intervention and after the first and third menstrual cycle. Method of measurement: Measuring time.</prim_outcome>
      <prim_outcome>The severity of pain. Timepoint: Before intervention and after the first and third menstrual cycle. Method of measurement: Visual analog scale.</prim_outcome>
      <prim_outcome>Symptoms of dysmenorrhea. Timepoint: Before intervention and after the first and third menstrual cycle. Method of measurement: Verbal scale Anthresh - Mylsum.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Arak University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2016-07-25</approval_date>
        <contact_name>Ethics Committe of Arak University of Medical Sciences</contact_name>
        <contact_address>Arak University of Medical Sciences, Basij Square, Sardasht, Arak, Iran Arak Markazi Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
